Abstract
Positron emission tomography (PET) imaging of Alzheimer's Disease (AD) offers the potential to provide early onset diagnosis and subsequent intervention, including guided treatment regimens. One of the restricting factors in clinical application of PET technology is the limited availability of radioligands with affinity to specific targets of interest. Given the short half-life of the most popular positron emitter currently used ((18)F; approximately 120 min.) extremely rapid and efficient radiochemistry methods are needed to ensure required compounds are prepared and purified for administration within the 2-3 half life practical limit. Recent efforts to combine microwave mediated synthesis with advanced catalysis in the synthesis of specific categories of AD imaging agents will be presented.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
